The 2026 regulatory map for psychedelic medicine.

Regulatory status is the most consequential variable in psychedelic medicine right now. It determines what trials can run, which drugs can be prescribed, and which operators are building something sustainable versus something that depends on a regulatory posture that may not hold. Here is where things actually stand, without the hype.

This is a working document. I update my own version of this every quarter. This is the May 2026 edition.

United States: FDA and the state layer

The FDA does not approve psychedelics as a category. It reviews specific compounds for specific indications. The current landscape has two distinct tracks:

Ketamine and esketamine. Ketamine is not a "scheduled" psychedelic in the same sense as psilocybin or MDMA. It is a Schedule III dissociative anesthetic with a long history of off-label psychiatric use. Esketamine (Spravato) received FDA approval in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation or behavior. This is the only FDA-approved psychedelic-adjacent treatment currently on the market. The evidence base for ketamine infusion (as opposed to esketamine nasal spray) is robust, but it operates largely in an off-label context without the same oversight infrastructure.

MDMA-assisted therapy. The FDA rejected Lykos Therapeutics' NDA for MDMA-assisted therapy for PTSD in August 2024, citing concerns about functional unblinding, insufficient data on abuse potential, and questions about site diversity and monitoring. The agency requested an additional Phase 3 trial. This is a significant setback. Whether it is a temporary obstacle or a more fundamental signal about FDA's approach to the category is still being read by the field.

Psilocybin. No psilocybin therapy is currently FDA-approved. COMPASS Pathways and Usona Institute both have active Phase 3 programs. COMP360 results are being actively analyzed. The FDA has granted Breakthrough Therapy designation to both compounds. Breakthrough designation accelerates the review process but does not guarantee approval.

State-level developments. Oregon and Colorado have implemented regulated psilocybin frameworks outside of the FDA drug approval pathway. Oregon's Measure 109 created a state-licensed facilitation model. Colorado's Proposition 122 created a similar framework. These are not medical approval pathways. They are public health frameworks that allow supervised, non-prescription access. The legal architecture is complex, and the liability and professional practice questions are not fully resolved. California's Senate Bill 58, which would have decriminalized personal possession, was vetoed. Expect continued ballot initiative activity in 2026.

United Kingdom: MHRA and the current constraints

The UK's Medicines and Healthcare products Regulatory Agency operates within a framework that currently schedules psilocybin, MDMA, LSD, and DMT as Class A controlled substances under the Misuse of Drugs Act 1971. Research exemptions exist, but they require specific Home Office licensing.

The Advisory Council on the Misuse of Drugs published a report in 2024 recommending rescheduling of certain psychedelics to facilitate research. As of this writing, the government has not acted on those recommendations.

COMPASS Pathways has conducted significant research in the UK, and there is a credible argument that the UK regulatory environment may move faster than the US if MHRA follows the ADCD recommendations and if Phase 3 results are compelling. Watch the 2026 parliamentary sessions.

Canada: Health Canada's Special Access Program

Canada has taken an incremental but meaningful approach through Health Canada's Special Access Program (SAP). The SAP allows individual patients with serious or life-threatening conditions to access drugs that are not yet approved when conventional therapies have failed.

Psilocybin has been accessed through the SAP for palliative care patients and for treatment-resistant depression under specific conditions. This is not approval; it is compassionate access. But it has created a small but real clinical infrastructure for psilocybin therapy in Canada that does not exist in the same form in the US or UK.

Canadian researchers have also been active contributors to the global evidence base. Several Phase 2 studies have run through Canadian academic centers.

European Union: EMA and the emerging picture

The European Medicines Agency has not yet reviewed any psychedelic compound for approval. The regulatory pathway in the EU requires a complete marketing authorization application, which requires completed Phase 3 data. No sponsor has submitted one.

Several EU member states, including the Netherlands and Germany, have created more permissive research environments. Germany's legalization of cannabis in 2024, while not directly relevant to psychedelics, signals political will toward evidence-based drug policy reform.

The EMA's parallel scientific advice process allows sponsors to get informal guidance before filing. COMPASS and potentially other sponsors have used this mechanism. The actual review timeline for any psychedelic compound in the EU is not before 2027 at the earliest.

What operators and investors need to watch

The regulatory questions that matter most to capital allocation in 2026 are these:

• Will FDA's MDMA rejection shape how other compounds' NDAs are constructed, particularly around blinding methodology and site monitoring?
• Will Oregon and Colorado's state frameworks generate safety and efficacy data that informs federal policy, or will they remain parallel systems?
• Will Health Canada expand SAP access, and does that create a faster pathway for Canadian-based operators?
• What does COMPASS's Phase 3 analysis show, and how does FDA respond to a psilocybin NDA?

None of these questions have clear answers yet. Anyone telling you they do is working from assumption, not data.

A note on reading regulatory documents

FDA advisory committee transcripts, Complete Response Letters, and briefing documents are public record. They are also where the actual reasoning lives. When you read a headline about an FDA decision, the primary source is the document, not the interpretation. I read the documents. If you want them summarized weekly, the signup is below.

Subscribe to Psilosignal